UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 25

Sortiert nach

Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes

Diabetes, obesity & metabolism, 2008-05, Vol.10 (5), p.376-386

2008

Volltextzugriff (PDF)

Durability of glycaemic control with dapagliflozin, an SGLT2 inhibitor, compared with saxagliptin, a DPP4 inhibitor, in patients with inadequately controlled type 2 diabetes

Diabetes, obesity & metabolism, 2019-11, Vol.21 (11), p.2564-2569

2019

Volltextzugriff (PDF)

Frequency of cancer events with saxagliptin in the SAVOR-TIMI 53 trial

Diabetes, obesity & metabolism, 2016-02, Vol.18 (2), p.186-190

2016

Volltextzugriff (PDF)

Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin

Archives of Endocrinology and Metabolism, 2018-08, Vol.62 (4), p.424-430

2018

Volltextzugriff (PDF)

Hypoglycaemia manifestations and recurrent events: Lessons from the SAVOR‐TIMI 53 outcome study

Diabetes, obesity & metabolism, 2017-07, Vol.19 (7), p.1045-1050

2017

Volltextzugriff (PDF)

Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer

Oncotarget, 2017-01, Vol.8 (2), p.3581-3590

2017

Volltextzugriff (PDF)

Baseline differences in the SAVOR trial

Diabetes, obesity & metabolism, 2015-12, Vol.17 (12), p.1202-1202

2015

Volltextzugriff (PDF)

Saxagliptin, a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

IDrugs : the investigational drugs journal, 2008-12, Vol.11 (12), p.906

Gallwitz, Baptist

2008

Volltextzugriff (PDF)

177 Lu-PSMA therapy : Current evidence for use in the treatment of patients with metastatic prostate cancer

Urologe. Ausgabe A, 2017-11, Vol.56 (11), p.1440

2017

Volltextzugriff (PDF)

Saxagliptin in type 2 diabetes

Drugs of today (Barcelona, Spain : 1998), 2010-02, Vol.46 (2), p.101-108

Billiones, Raquel

2010

Volltextzugriff (PDF)

Saxagliptin + metformin. Mostly disadvantages

Prescrire international, 2013-02, Vol.22 (135), p.40-40

2013

Volltextzugriff (PDF)

Saxagliptin and tuberculosis

Prescrire international, 2013-01, Vol.22 (134), p.17-17

2013

Volltextzugriff (PDF)

Saxagliptin. No more effective than other gliptins, but a high potential for drug interactions

Prescrire international, 2011-02, Vol.20 (113), p.33-37

2011

Volltextzugriff (PDF)

Enalapril and lisinopril in renovascular hypertension--antihypertensive and hormonal effects of two new angiotensin-converting-enzyme (ACE) inhibitors. A preliminary report

Scandinavian journal of urology and nephrology. Supplement, 1984, Vol.79, p.103

1984

Volltextzugriff (PDF)

Ornithine aspartate in hepatic encephalopathy: an established new therapeutic approach. Overview and results of current randomized studies

Zeitschrift fur arztliche Fortbildung, 1994-09, Vol.88 (9), p.673

1994

Volltextzugriff (PDF)

Enalapril, a nonsulfhydryl angiotensin-converting enzyme inhibitor

Clinical pharmacy, 1985-01, Vol.4 (1), p.27

1985

Volltextzugriff (PDF)

Overview: the role of angiotensin-converting enzyme inhibitors in cardiovascular therapy

Federation proceedings, 1984-04, Vol.43 (5), p.1314

1984

Volltextzugriff (PDF)

Efficacy and tolerability of lisinopril compared with extended release felodipine in patients with essential hypertension. Danish Cooperative Study Group

Clinical and experimental hypertension. Part A, Theory and practice, 1992, Vol.14 (6), p.1095

Jensen, H A

1992

Volltextzugriff (PDF)

NAAGA versus disodium cromoglycate in perennial allergic rhinopathy: results of a multicenter study

Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis, 1989-05, Vol.78 (20), p.585

1989

Volltextzugriff (PDF)

Effectiveness and tolerance of the C3 convertase inhibitor, N-acetyl-aspartyl-magnesium glutamate with anti-allergic action. Results of a double-blind study

Arzneimittel-Forschung, 1989-02, Vol.39 (2), p.270

1989

Volltextzugriff (PDF)

Initial evaluation of the non-sulfhydryl-containing converting enzyme inhibitor MK-521 in hypertensive humans

Federation proceedings, 1984-01, Vol.43 (5), p.1333

1984

Volltextzugriff (PDF)

Captopril and enalapril: angiotensin converting enzyme (ACE) inhibitors

Rational drug therapy, 1984-03, Vol.18 (3), p.1

1984

Volltextzugriff (PDF)

A randomized controlled trial of the efficacy and safety of saxagliptin as add-on therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea

Diabetes, obesity & metabolism, 2014-05, Vol.16 (5), p.443-450

2014

Volltextzugriff (PDF)

Tolerability of saxagliptin in patients with inadequately controlled type 2 diabetes: results from 6 phase III studies

Journal of managed care pharmacy, 2014-02, Vol.20 (2), p.120-129

Davidson, Jaime A

2014

Volltextzugriff (PDF)

Reproducibility of acute captopril-induced renal insufficiency with enalapril

Klinische Wochenschrift, 1984-01, Vol.62 (1), p.43

Cremer, W

1984

Volltextzugriff (PDF)

1 – 25 von 25

Suche als RSS-Feed

Aktive Filter

KollektionSage Journals

Nur zeigenGeprüft (Peer-Review)

KollektionMEDLINE

ThemaDipeptides - Adverse Effects

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Mit Volltextzugriff
(10)

Publikationsform

Artikel
(25)

Sprache

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes

Durability of glycaemic control with dapagliflozin, an SGLT2 inhibitor, compared with saxagliptin, a DPP4 inhibitor, in patients with inadequately controlled type 2 diabetes

Frequency of cancer events with saxagliptin in the SAVOR-TIMI 53 trial

Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin

Hypoglycaemia manifestations and recurrent events: Lessons from the SAVOR‐TIMI 53 outcome study

Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer

Baseline differences in the SAVOR trial

Saxagliptin, a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

177 Lu-PSMA therapy : Current evidence for use in the treatment of patients with metastatic prostate cancer

Saxagliptin in type 2 diabetes

Saxagliptin + metformin. Mostly disadvantages

Saxagliptin and tuberculosis

Saxagliptin. No more effective than other gliptins, but a high potential for drug interactions

Enalapril and lisinopril in renovascular hypertension--antihypertensive and hormonal effects of two new angiotensin-converting-enzyme (ACE) inhibitors. A preliminary report

Ornithine aspartate in hepatic encephalopathy: an established new therapeutic approach. Overview and results of current randomized studies

Enalapril, a nonsulfhydryl angiotensin-converting enzyme inhibitor

Overview: the role of angiotensin-converting enzyme inhibitors in cardiovascular therapy

Efficacy and tolerability of lisinopril compared with extended release felodipine in patients with essential hypertension. Danish Cooperative Study Group

NAAGA versus disodium cromoglycate in perennial allergic rhinopathy: results of a multicenter study

Effectiveness and tolerance of the C3 convertase inhibitor, N-acetyl-aspartyl-magnesium glutamate with anti-allergic action. Results of a double-blind study

Initial evaluation of the non-sulfhydryl-containing converting enzyme inhibitor MK-521 in hypertensive humans

Captopril and enalapril: angiotensin converting enzyme (ACE) inhibitors

A randomized controlled trial of the efficacy and safety of saxagliptin as add-on therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea

Tolerability of saxagliptin in patients with inadequately controlled type 2 diabetes: results from 6 phase III studies

Reproducibility of acute captopril-induced renal insufficiency with enalapril

Aktive Filter

Suchergebnisse filtern